Alteration of a Clinically Meaningful Outcome in the Natural History of Alzheimer's Disease by Cholinesterase Inhibition
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Objectives: To describe the effect of cholinesterase inhibitors (CEIs) on the natural course of Alzheimer's disease (AD) using clinically meaningful outcomes. Design: Cross‐sectional and longitudinal study. Setting: Referral dementia clinic. Participants: One hundred thirty‐five matched pairs of patients with probable AD. Measurements: The risk of AD patients being classified as slow progressors (Mini‐Mental State Examination (MMSE) score change ≤2 at 1‐year follow‐up) was examined as a function of treatment with CEIs. A logistic regression analysis, controlling for age, sex, education level, MMSE score, Blessed Dementia Rating Scale (BDRS) for activities of daily living (ADLs), extrapyramidal signs, psychosis, major depression, and use of antidepressants, antipsychotics, and sedative/hypnotics determined the factors that best predict slow progression and nursing home admission. Results: Eighty‐one (60%) of the patients on CEIs and 53 (39%) of the patients who never used CEIs were considered slow progressors ( P= .001) at 1‐year follow‐up. Slow progression was associated only with CEI use (relative risk (RR)=2.45, 95% confidence interval (CI)=1.45–4.16), and sedative/hypnotics use was associated with a MMSE change of 3 points or more (RR=0.35, 95% CI=0.13–0.93). CEI use had a protective effect on nursing home admission (RR=0.095, 95% CI=0.03–0.30), whereas higher scores on the BDRS for ADLs increased risk of admission at 24‐ and 36‐month follow‐up. Conclusion: CEI use had a clinically meaningful effect on the natural history of AD. Patients taking CEIs were 2.5 times more likely to progress slowly and had a lower risk of nursing home admission after 2 years, even after controlling for multiple factors that can alter the course of the disease, and a slower rate of decline during the first year of follow‐up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117
DeKosky, S. T., Ikonomovic, M. D., Styren, S. D., Beckett, L., Wisniewski, S., Bennett, D. A., Cochran, E. J., Kordower, J. H., & Mufson, E. J. (2002) · Annals of Neurology · doi:10.1002/ana.10069 · Cited by 686
Self-citationFarlow, M., Anand, R., Messina Jr, J., Hartman, R., & Veach, J. (2000) · European Neurology · doi:10.1159/000008243 · Cited by 332 · cited 5×
“96 Any time at follow-up 11 (14) 6 (11) 5 (9) 6 (7) 1.”
InfluentialChronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease
Doody, R. S., Dunn, J. K., Clark, C. M., Farlow, M., Foster, N. L., Liao, T., Gonzales, N., Lai, E., & Massman, P. (2001) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051272 · Cited by 118
Cited by
Statins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub3 · Cited by 490
Liss, J. L., Seleri Assunção, S., Cummings, J., Atri, A., Geldmacher, D. S., Candela, S. F., Devanand, D. P., Fillit, H. M., Susman, J., Mintzer, J., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13244 · Cited by 312
Early identification and treatment of Alzheimer's disease: Social and fiscal outcomes
Weimer, D. L., & Sager, M. A. (2009) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2009.01.028 · Cited by 257
Pre-Diagnosis Excess Acute Care Costs in Alzheimer’s Patients among a US Medicaid Population
Geldmacher, D. S., Kirson, N. Y., Birnbaum, H. G., Eapen, S., Kantor, E., Cummings, A. K., & Joish, V. N. (2013) · Applied Health Economics and Health Policy · doi:10.1007/s40258-013-0038-9 · Cited by 53
Cunningham, E. L., Todd, S. A., Passmore, P., Bullock, R., & McGuinness, B. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004034.pub4 · Cited by 45
Metadata
- Authors
- Lopez, O. L., Becker, J. T., Saxton, J., Sweet, R. A., Klunk, W., & DeKosky, S. T.
- Venue
- Journal of the American Geriatrics Society
- Publisher
- Wiley
- Published
- 2004-12-22
- Volume
- 53
- Issue
- 1
- Pages
- 83-87
- ISSN
- 0002-8614 (ISSN-L)
- 1532-5415
- OpenAlex
- W1572510728
- Cited by
- 106
- References
- 4
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alteration of a Clinically Meaningful Outcome in the Natural History of Alzheimer's Disease by Cholinesterase Inhibition. https://app.cochat.ai/papers/10.1111/j.1532-5415.2005.53015.x
- The paper
- Lopez, O. L., Becker, J. T., Saxton, J., Sweet, R. A., Klunk, W., & DeKosky, S. T. (2005). Alteration of a Clinically Meaningful Outcome in the Natural History of Alzheimer's Disease by Cholinesterase Inhibition. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.2005.53015.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.